CPRX News and Press, Catalyst Pharmaceuticals Inc. From 02/11/19

Catalyst Pharmaceuticals ( CPRX +2.4% ) says that the net price per year for LEMS med Firdapse (amifampridine) will be $300K - 318,750 per year, representing about a 15 - 20% discount off the $375K list price. The net price includes rebates to insurers and other discounts. More news on...

CORAL GABLES, Fla., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, toda...

Catalyst Pharmaceuticals (NASDAQ: CPRX ) is down  4%  premarket on light volume on the heels of the news that Sen. Bernie Sanders (I-VT) has sent it a letter asking why Firdapse (amifampridine), approved by the FDA about two months ago for the treatment of a rare autoimmune disor...